Tenecteplase vs Alteplase in Mechanical Prosthetic Heart Valve Thrombosis: The TENET Randomized Clinical Trial
For patients presenting with symptomatic prosthetic valve thrombosis (PVT) after mechanical heart valve replacement, thrombolytic therapy with alteplase is accepted as a first-line therapeutic alternative. The utility of tenecteplase compared with conventional regimens remains unstudied, to the authors' knowledge, in this patient population.
Clonal Hematopoiesis and Incident Heart Failure
Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with acquired preleukemic variants, has been associated with cardiometabolic diseases, including heart failure (HF). However, prior studies have lacked power to examine less common CHIP driver variants and have not investigated potential mediators of the CHIP-HF association.
Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial
Transthyretin amyloid cardiomyopathy (ATTR-CM) is underdiagnosed despite expanding treatment options.
Carotid Artery Stenosis-An Impactful Bias in Ischemic Stroke Classification
Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial
Anthracyclines, which are key to many chemotherapeutic protocols, have been associated with increased vascular stiffness, a major factor associated with cardiovascular morbidity and mortality. There is no evidence-based intervention to prevent anthracycline-associated vascular dysfunction.
Chronic Kidney Disease Prevalence and Awareness Among US Adults
Chronic kidney disease (CKD) is common and often coexists with cardiometabolic risk factors and cardiovascular disease (CVD).
Detecting Atherosclerosis-From Autopsy to Angiography With Computed Tomography
Blood Pressure in Adolescence and Atherosclerosis in Middle Age
Elevated blood pressure (BP) in adolescence has been linked to higher risk of cardiovascular disease mortality, as well as surrogate markers of atherosclerosis, such as carotid intima-media thickness and coronary artery calcification. However, these markers do not fully capture the complex spectrum of subclinical atherosclerotic cardiovascular disease.
A Contemporary Look at the Landscape of Treatment of Tricuspid Regurgitation: A Review
Untreated severe tricuspid regurgitation carries a poor prognosis. We aim to provide a contemporary review of the anatomy, clinical manifestations, and diagnostic and management strategies, including medical, surgical and transcatheter options. By synthesizing current knowledge, this review seeks to equip clinicians with the insights necessary to navigate the complexities of TR treatment.
T-TEER for Severe Tricuspid Regurgitation in the TRILUMINATE Pivotal Trial
Clonal Hematopoiesis-An Opportunity to Confront the Heart Failure Epidemic
Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers
Exercise may lead to disease progression and higher risk of sudden death in individuals with genetic cardiomyopathies, but the effects of exercise among individuals carrying a cardiomyopathy-associated variant without clinical manifestations (G+P-) are unclear.
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial
The Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) randomized clinical trial showed that in patients with subclinical atrial fibrillation (SCAF) apixaban, compared with aspirin, reduced stroke/systemic embolism but increased major bleeding.
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension
Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE).
